Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Targeting GNE myopathy: A dual prodrug approach for the delivery of N-acetylmannosamine 6-phosphate

Morozzi, Chiara, Sedláková, Jana, Serpi, Michaela, Avigliano, Marialuce, Carbajo, Rosangela, Sandoval, Lucia, Valles-Ayoub, Yadira, Crutcher, Patrick, Thomas, Stephen and Pertusati, Fabrizio 2019. Targeting GNE myopathy: A dual prodrug approach for the delivery of N-acetylmannosamine 6-phosphate. Journal of Medicinal Chemistry , -. 10.1021/acs.jmedchem.9b00833
Item availability restricted.

[img] PDF - Accepted Post-Print Version
Restricted to Repository staff only until 6 August 2020 due to copyright restrictions.

Download (1MB)


ProTides comprise an important class of prodrugs currently marketed and developed as antiviral and anticancer therapies. The ProTide technology employs phosphate masking groups capable of providing more favorable druglike properties and an intracellular activation mechanism for enzyme-mediated release of a nucleoside monophosphate. Herein, we describe the application of phosphoramidate chemistry to 1,3,4-O-acetylated N-acetylmannosamine (Ac3ManNAc) to deliver ManNAc-6-phosphate (ManNAc-6-P), a critical intermediate in sialic acid biosynthesis. Sialic acid deficiency is a hallmark of GNE myopathy, a rare congenital disorder of glycosylation (CDG) caused by mutations in GNE that limit the production of ManNAc-6-P. Synthetic methods were developed to provide a library of Ac3ManNAc-6-phosphoramidates that were evaluated in a series of studies for their potential as a treatment for GNE myopathy. Prodrug 12b showed rapid activation in a carboxylesterase (CPY) enzymatic assay and favorable ADME properties, while also being more effective than ManNAc at increasing sialic acid levels in GNE-deficient cell lines. These results provide a potential platform to address substrate deficiencies in GNE myopathy and other CDGs.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Pharmacy
Publisher: American Chemical Society
ISSN: 0022-2623
Date of First Compliant Deposit: 4 September 2019
Date of Acceptance: 6 August 2019
Last Modified: 15 Mar 2020 06:04

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics